上海金畔生物科技正规代理Trilink产品，zui近市场出现Trilink的假货，为了您的实验安全请选择正牌代理。 :
TriLink BioTechnologies——高品质常规/特殊核苷酸产品
TriLink BioTechnologies公司是世界的核酸修饰技术领域的，成立于1996年，总部设在San Diego，California。TriLink公司致力于高品质核酸修饰产品的研发和生产，提供包括核苷酸、常规及核苷三磷酸特殊修饰的寡核苷酸定制（oligonucleotides），m RNA合成，CleanAmp?PCR产品，phosphoramidites和其他小分子在内的众多产品。近二十年来，TriLink一直是诊断和OEM市场核酸产品供应的行业，产品应用于基因治疗，核苷类化疗，寡核苷酸治疗和诊断领域。此外，TriLink还可提供特殊核苷酸、m RNA定制，合同研究服务和ISO/ QSR标准的cGMP生产设施。TriLink完善的产品及研发服务解决方案有助于推动药物发现和生物医学研究。
经过18年的发展， TriLink已经成为高品质RNA合成领域的，为广大科研工作者提供的mRNA及长链RNA（长可达几个Kb），并且定制修饰。同时我们也提供成品mRNA产品，包括报告基因及 mRNA表达因子。
Genome Editing mRNA
Plasmids and viral vectors have traditionally been used in genome editing to express the required proteins inside cells or an organism. However, editing DNA carries a risk. Double stranded DNA breaks catalyze insertion of DNA at the cut site. At some substantial frequency, the protein expression vectors can integrate, which can lead to continuous expression of the nuclease or a previously silent sequence.
Now mRNA is being used in genome editing to transiently express the required proteins. With no risk of insertional mutagenesis, it is a powerful tool. Additionally synthetic mRNA, which mimics fully processed, capped and polyadenylated mRNA, can be produced in large quantities by in vitro transcription and modified to reduce innate immune stimulation.
产品如下：
| 货号 |
品名 |
规格 |
价格 |
品牌 |
| Genome Editing mRNA |
|
| L-7206 |
CleanCap™ Cas9 mRNA (modified) |
20 µgrams |
2550 |
TriLink BioTechnologies |
| L-7206 |
CleanCap™ Cas9 mRNA (modified) |
100 µgrams |
6035 |
TriLink BioTechnologies |
| L-7206 |
CleanCap™ Cas9 mRNA (modified) |
1 mg |
31875 |
TriLink BioTechnologies |
| L-7206 |
CleanCap™ Cas9 mRNA (modified) |
5 mg (5 x 1 mg) |
114750 |
TriLink BioTechnologies |
| L-7211 |
CleanCap™ Cre mRNA (5moU) |
5moU |
询价 |
TriLink BioTechnologies |
| L-7207 |
CleanCap™ Cas9 Nickase mRNA (5moU) |
20 µgrams |
2550 |
TriLink BioTechnologies |
| L-7207 |
CleanCap™ Cas9 Nickase mRNA (5moU) |
100 µgrams |
6035 |
TriLink BioTechnologies |
| L-7207 |
CleanCap™ Cas9 Nickase mRNA (5moU) |
1 mg |
31875 |
TriLink BioTechnologies |
| L-7207 |
CleanCap™ Cas9 Nickase mRNA (5moU) |
5 mg (5 x 1 mg) |
114750 |
TriLink BioTechnologies |
| L-7606 |
CleanCap™ Cas9 mRNA |
20 µgrams |
2125 |
TriLink BioTechnologies |
| L-7606 |
CleanCap™ Cas9 mRNA |
100 µgrams |
5015 |
TriLink BioTechnologies |
| L-7606 |
CleanCap™ Cas9 mRNA |
1 mg |
26775 |
TriLink BioTechnologies |
| L-7606 |
CleanCap™ Cas9 mRNA |
5 mg (5 x 1 mg) |
96050 |
TriLink BioTechnologies |
Zinc-finger Nuclease mRNA (ZFN mRNA)
Zinc-finger nucleases (ZFNs) were the first widely applicable site specific genome editing tools. Recently, several studies have shown that ZFNs can have off-target effects at non-targeted chromosomal sites that are similar in sequence to the intended target site. For this reason, there is a move to transient ZFN expression using mRNA based vectors. TriLink’s custom mRNA transcription service includes ZFN mRNA. Request a quote today!
L-7206
CleanCap™ Cas9 mRNA (modified)
CleanCap™ CRISPR Associated Protein 9 mRNA (U-modified)
mRNA Length: 4,521 nucleotides
Concentration: 1.0 mg/mL
Buffer: 1 mM Sodium Citrate, pH 6.4
Identity & Purity:
Agarose Gel Mobility; Pass
Concentration ± 5%; Pass
Product Insert
SDS
Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.
Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein.
This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, substituted with a modified uridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
Certificate(s) of Analysis
TD-OA02A
T1-CHZ01A-1
L-7206 is a replacement product for L-6125 and L-6129.
Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.
CleanCap™ Cre mRNA (5moU)
CleanCap™ NLS-Cre Recombinase mRNA (5-methoxyuridine)
Contact us today to preorder!
Catalog Number: L-7211
mRNA Length: 1,437 nucleotides
Concentration: 1.0 mg/mL
Buffer: 1 mM Sodium Citrate, pH 6.4
Identity & Purity:
Agarose Gel Mobility; Pass
Concentration ± 5%; Pass
Product Insert
SDS
NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites.
This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
L-7211 is a replacement for L-6108.
Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.
L-7606
CleanCap™ Cas9 mRNA
CleanCap™ CRISPR Associated Protein 9 mRNA
mRNA Length: 4,521 nucleotides
Concentration: 1.0 mg/mL
Buffer: 1 mM Sodium Citrate, pH 6.4
Identity & Purity:
Agarose Gel Mobility; Pass
Concentration ± 5%; Pass
Product Insert
SDS
Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.
Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein.
This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, and optimized for mammalian systems. It mimics a fully processed mature mRNA.
